

## Technology Advisory Interests Register

**Topic: Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Satish Venkateshan	TAC Committee Member	Financial	Regeneron is developing therapeutics for a broad range of diseases including in solid tumours. I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.	19/11/2025 12/02/2026	It was agreed that Satish's declaration would not prevent them from participating in discussions on this appraisal
Jon Tosh	TAC Committee Member	Financial	I work for GSK, who do not have any active projects in this area.	09/12/2025	It was agreed that Jon's declaration would not prevent them from participating in discussions on this appraisal
Professor John Bridgewater	Expert	Direct – financial	Payment for advisory boards and preceptorship programme from Jazz: 2023-4 £9,700 2024-5 £8,700 2025-6 (to date) £450  This compares to that received from Incyte:	16/07/2025 03/03/2026	It was agreed that Professor Bridgewater's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			2023-4 £7,500 2024-5 £7,000 as well as approximately £150,000 indirect research funding (University of Birmingham)		
		Direct – non-financial	Travel support for ESMO 2025 (October 2025) TBD		
Paul Howard	Expert	Financial	<p>I am employed by AMMF – The Cholangiocarcinoma Charity, which has received grant and sponsorship funding from Jazz Pharmaceuticals to support projects including our annual 3-day European cholangiocarcinoma conference, and our European website which is translated into eight additional languages. Details of these financial contributions were declared by AMMF and Jazz Pharmaceuticals in their submissions for this appraisal.</p> <p>I would like to note that AMMF has a strict policy for how it works with the pharmaceutical industry. Our projects are supported by multiple industry partners, and they have no editorial input or control.</p>	22/07/2025 03/03/2026	It was agreed that Paul's declaration would not prevent them from providing expert advice to the committee